Literature DB >> 1768567

Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.

D A Smith1, M H Chandler, S I Shedlofsky, P J Wedlund, R A Blouin.   

Abstract

1. The disposition of hexobarbitone enantiomers before and after rifampicin treatment (600 mg daily for 14 days) was investigated in six young (29 +/- 3 years old) and six elderly (71 +/- 4 years old) healthy male volunteers. Hexobarbitone was given as a single 500 mg oral dose of the racemate. 2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects. 3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768567      PMCID: PMC1368555     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery.

Authors:  D D Breimer; W Zilly; E Richter
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

Review 2.  Stereoselective drug metabolism and its significance in drug research.

Authors:  B Testa; J M Mayer
Journal:  Prog Drug Res       Date:  1988

3.  Stimulatory effect of vegetables on intestinal drug metabolism in the rat.

Authors:  E J Pantuck; K C Hsiao; W D Loub; L W Wattenberg; R Kuntzman; A H Conney
Journal:  J Pharmacol Exp Ther       Date:  1976-08       Impact factor: 4.030

4.  Intestinal microsomal enzyme induction by rifampicin.

Authors:  I Hegazy; M Khayyal
Journal:  Chemioterapia       Date:  1987-06

5.  Metabolism and cytochrome P-450 binding spectra of (+)- and (-)-hexobarbital in rat liver microsomes.

Authors:  E Degkwitz; V Ullrich; H Staudinger
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1969-05

6.  Interactions of the hexobarbital enantiomers with rat liver microsomes.

Authors:  D R Feller; W C Lubawy
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

7.  The metabolic fate of hexobarbital in the rat.

Authors:  R R Holcomb; N Gerber; M T Bush
Journal:  J Pharmacol Exp Ther       Date:  1974-01       Impact factor: 4.030

8.  Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.

Authors:  H H Zhou; L B Anthony; A J Wood; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 9.  Stereoselectivity: an issue of significant importance in clinical pharmacology.

Authors:  Y W Lam
Journal:  Pharmacotherapy       Date:  1988       Impact factor: 4.705

10.  Pharmocokinetics of hexobarbital in man after intravenous infusion.

Authors:  D D Breimer; C Honhoff; W Zilly; E Richter; J M van Rossum
Journal:  J Pharmacokinet Biopharm       Date:  1975-02
View more
  13 in total

Review 1.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 2.  Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.

Authors:  R Mehvar; F Jamali
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

3.  MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.

Authors:  Dianke Yu; Bridgett Green; William H Tolleson; Yaqiong Jin; Nan Mei; Yongli Guo; Helen Deng; Igor Pogribny; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2015-08-19       Impact factor: 5.858

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Chirality in new drug development. Clinical pharmacokinetic considerations.

Authors:  R L Nation
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 6.  Pharmacokinetic studies in elderly people. Are they necessary?

Authors:  P Crome; R J Flanagan
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

7.  Chiral bioequivalence: effect of absorption rate on racemic etodolac.

Authors:  J R Boni; J M Korth-Bradley; L S Richards; S T Chiang; D R Hicks; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man.

Authors:  S Wanwimolruk; W Kang; P F Coville; S Viriyayudhakorn; S Thitiarchakul
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.